MA65277B1 - Inhibiteurs de l'inflammasome nlrp3 - Google Patents
Inhibiteurs de l'inflammasome nlrp3Info
- Publication number
- MA65277B1 MA65277B1 MA65277A MA65277A MA65277B1 MA 65277 B1 MA65277 B1 MA 65277B1 MA 65277 A MA65277 A MA 65277A MA 65277 A MA65277 A MA 65277A MA 65277 B1 MA65277 B1 MA 65277B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- nlrp3 inflammasome
- useful
- inflammasome inhibitors
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
L'invention concerne d'une manière générale des composés de formule (I), et des sels pharmaceutiquement acceptables de ceux-ci, R1, R2A, R2B, R2C, R2D, W, X, Y et Z ayant les significations définies dans la description. De tels composés sont utiles pour inhiber l'activité de l'inflammasome NLRP3 et peuvent être utiles en tant qu'agents thérapeutiques. L'invention concerne également l'utilisation de tels composés pour traiter ou prévenir des maladies et des affections dans lesquelles l'inflammasome NLRP3 est impliqué. L'invention concerne en outre des compositions comprenant de tels composés.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163217970P | 2021-07-02 | 2021-07-02 | |
| EP22744149.0A EP4363406B1 (fr) | 2021-07-02 | 2022-07-01 | Inhibiteurs de l'inflammasome nlrp3 |
| PCT/EP2022/068292 WO2023275366A1 (fr) | 2021-07-02 | 2022-07-01 | Inhibiteurs de l'inflammasome nlrp3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA65277B1 true MA65277B1 (fr) | 2025-12-31 |
Family
ID=82611090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA65277A MA65277B1 (fr) | 2021-07-02 | 2022-07-01 | Inhibiteurs de l'inflammasome nlrp3 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US11970463B2 (fr) |
| EP (2) | EP4628490A3 (fr) |
| JP (1) | JP2024523623A (fr) |
| KR (1) | KR20240031343A (fr) |
| CN (1) | CN117580826A (fr) |
| AR (1) | AR126351A1 (fr) |
| AU (2) | AU2022304254B2 (fr) |
| BR (1) | BR112023026976A2 (fr) |
| CA (1) | CA3224513A1 (fr) |
| CL (1) | CL2023003939A1 (fr) |
| CO (1) | CO2024000565A2 (fr) |
| CR (1) | CR20240038A (fr) |
| DK (1) | DK4363406T3 (fr) |
| DO (1) | DOP2024000002A (fr) |
| EC (1) | ECSP24008862A (fr) |
| ES (1) | ES3054790T3 (fr) |
| FI (1) | FI4363406T3 (fr) |
| HR (1) | HRP20251513T1 (fr) |
| IL (1) | IL309680A (fr) |
| LT (1) | LT4363406T (fr) |
| MA (1) | MA65277B1 (fr) |
| MX (1) | MX2024000234A (fr) |
| PE (1) | PE20250122A1 (fr) |
| PL (1) | PL4363406T3 (fr) |
| PT (1) | PT4363406T (fr) |
| RS (1) | RS67463B1 (fr) |
| SI (1) | SI4363406T1 (fr) |
| SM (1) | SMT202500441T1 (fr) |
| TW (1) | TW202321201A (fr) |
| UY (1) | UY39839A (fr) |
| WO (1) | WO2023275366A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| TW202313577A (zh) | 2021-06-04 | 2023-04-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| TW202319055A (zh) | 2021-07-21 | 2023-05-16 | 日商安斯泰來製藥股份有限公司 | 縮環噠嗪（ｐｙｒｉｄａｚｉｎｅ）化合物 |
| CR20240093A (es) | 2021-08-25 | 2024-05-23 | Ptc Therapeutics Inc | Inhibidores de NLRP3 |
| WO2023051761A1 (fr) * | 2021-09-30 | 2023-04-06 | 成都奥睿药业有限公司 | Utilisation pharmaceutique et procédé de préparation d'un dérivé d'hétéroaryl-phtalazine substitué |
| WO2023066377A1 (fr) | 2021-10-22 | 2023-04-27 | 索智生物科技（浙江）有限公司 | Composé contenant de l'azote, son procédé de préparation et son application |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| WO2024141534A1 (fr) * | 2022-12-28 | 2024-07-04 | Astrazeneca Ab | Formes cristallines d'inhibiteurs de l'inflammasome nlrp3, processus chimiques et composés chimiques |
| KR20250106322A (ko) | 2022-12-28 | 2025-07-09 | 장춘 진사이언스 파마슈티컬 씨오., 엘티디. | 피리다진계 nlrp3 억제제 화합물, 약학 조성물 및 이의 제조 방법과 용도 |
| KR20260027946A (ko) | 2023-06-02 | 2026-03-03 | 머크 샤프 앤드 돔 엘엘씨 | Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클 |
| TW202521535A (zh) * | 2023-11-20 | 2025-06-01 | 美商凡特斯治療美國公司 | 用於抑制ＮＬＲＰ３之固態游離鹼形式的５－氯－２－（４－（（２－羥基－２－甲基丙基）胺基）吡啶并［３，４－ｄ］嗒嗪－１－基）酚及其用途 |
| WO2025153532A1 (fr) | 2024-01-16 | 2025-07-24 | NodThera Limited | Polythérapies faisant intervenir des inhibiteurs de nlrp3 et des agonistes de glp-1 |
| WO2026006510A1 (fr) * | 2024-06-26 | 2026-01-02 | Virginia Commonwealth University | Composés utilisés en tant qu'inhibiteurs de nlrp3, compositions et utilisations associées |
| WO2026002229A1 (fr) * | 2024-06-28 | 2026-01-02 | 长春金赛药业有限责任公司 | Composé inhibiteur de nlrp3, son procédé de préparation et son utilisation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006004589A2 (fr) | 2004-05-08 | 2006-01-12 | Neurogen Corporation | Pyridazines 3-aryl-5,6-disubstituees |
| KR20200087759A (ko) * | 2017-11-09 | 2020-07-21 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| CN115279739B (zh) | 2020-03-27 | 2025-07-22 | 尼科治疗有限公司 | 取代哒嗪化合物 |
| WO2022135567A1 (fr) * | 2020-12-25 | 2022-06-30 | 上海拓界生物医药科技有限公司 | Composé contenant de la pyridazine et son utilisation médicinale |
| EP4289823A4 (fr) | 2021-02-08 | 2025-02-26 | Medshine Discovery Inc. | Dérivés de pyridazine phénol substitués |
| US11319319B1 (en) * | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CA3218212A1 (fr) | 2021-04-28 | 2022-11-03 | Astellas Pharma Inc. | Compose triazine substitue |
| EP4362946A4 (fr) | 2021-06-29 | 2025-05-21 | Zomagen Biosciences Ltd | Modulateurs de nlrp3 |
-
2022
- 2022-07-01 LT LTEPPCT/EP2022/068292T patent/LT4363406T/lt unknown
- 2022-07-01 CR CR20240038A patent/CR20240038A/es unknown
- 2022-07-01 WO PCT/EP2022/068292 patent/WO2023275366A1/fr not_active Ceased
- 2022-07-01 MA MA65277A patent/MA65277B1/fr unknown
- 2022-07-01 SI SI202230216T patent/SI4363406T1/sl unknown
- 2022-07-01 PT PT227441490T patent/PT4363406T/pt unknown
- 2022-07-01 AU AU2022304254A patent/AU2022304254B2/en active Active
- 2022-07-01 JP JP2023580488A patent/JP2024523623A/ja active Pending
- 2022-07-01 RS RS20251208A patent/RS67463B1/sr unknown
- 2022-07-01 CA CA3224513A patent/CA3224513A1/fr active Pending
- 2022-07-01 KR KR1020247003701A patent/KR20240031343A/ko active Pending
- 2022-07-01 MX MX2024000234A patent/MX2024000234A/es unknown
- 2022-07-01 EP EP25190541.0A patent/EP4628490A3/fr active Pending
- 2022-07-01 IL IL309680A patent/IL309680A/en unknown
- 2022-07-01 DK DK22744149.0T patent/DK4363406T3/da active
- 2022-07-01 BR BR112023026976A patent/BR112023026976A2/pt unknown
- 2022-07-01 EP EP22744149.0A patent/EP4363406B1/fr active Active
- 2022-07-01 ES ES22744149T patent/ES3054790T3/es active Active
- 2022-07-01 FI FIEP22744149.0T patent/FI4363406T3/fi active
- 2022-07-01 AR ARP220101723A patent/AR126351A1/es unknown
- 2022-07-01 HR HRP20251513TT patent/HRP20251513T1/hr unknown
- 2022-07-01 SM SM20250441T patent/SMT202500441T1/it unknown
- 2022-07-01 PL PL22744149.0T patent/PL4363406T3/pl unknown
- 2022-07-01 TW TW111124687A patent/TW202321201A/zh unknown
- 2022-07-01 US US17/810,367 patent/US11970463B2/en active Active
- 2022-07-01 PE PE2023003486A patent/PE20250122A1/es unknown
- 2022-07-01 CN CN202280045960.2A patent/CN117580826A/zh active Pending
- 2022-07-04 UY UY0001039839A patent/UY39839A/es unknown
-
2023
- 2023-12-28 CL CL2023003939A patent/CL2023003939A1/es unknown
-
2024
- 2024-01-02 DO DO2024000002A patent/DOP2024000002A/es unknown
- 2024-01-24 CO CONC2024/0000565A patent/CO2024000565A2/es unknown
- 2024-02-02 EC ECSENADI20248862A patent/ECSP24008862A/es unknown
- 2024-03-21 US US18/612,849 patent/US12503445B2/en active Active
-
2025
- 2025-09-02 AU AU2025223957A patent/AU2025223957A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA65277B1 (fr) | Inhibiteurs de l'inflammasome nlrp3 | |
| MA27957A1 (fr) | Agents derivatifs de quinolinone comme inhibiteurs de tyrosine kinase | |
| MA28064A1 (fr) | Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases | |
| NO20071042L (no) | 5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer | |
| TNSN05298A1 (fr) | Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases | |
| TN2009000138A1 (fr) | Biaryl-ether-urees | |
| EP2597953A4 (fr) | Méthode de traitement de maladies ophtalmiques à l'aide de composés d'inhibiteurs de kinase sous forme de promédicaments | |
| TNSN04151A1 (fr) | Derives de nicotinamide utiles comme inhibiteurs de pde4 | |
| MA30208B1 (fr) | Derives de pyrimidine utilises en tant qu'inhibiteurs de kinase pi -3 | |
| MA27808A1 (fr) | Derives de quinoleine utilises en tant qu'inhibiteurs de la phosphodiesterase | |
| ATE365742T1 (de) | 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren | |
| EA200000871A1 (ru) | Ингибиторы фосфолипазных ферментов | |
| TR200400342T4 (tr) | Farnezil protein transferazı önlemek için kinolin türevleri. | |
| EP1562897A4 (fr) | Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer | |
| MA30075B1 (fr) | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
| MA30313B1 (fr) | Amines secondaires en tant qu'inhibiteurs de la renine | |
| ZA200408283B (en) | 7-aryl-3,9-diazabicyclo (3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardivascular or rental diseases | |
| MA49956B1 (fr) | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak | |
| MA27491A1 (fr) | Derives de phenyl-ou heteroarylamino-alcanes comme antagonistes ou recepteur ip | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| MA30296B1 (fr) | Nouvelles amines | |
| MA29267B1 (fr) | Cyclopropyl-(2, 3-dimethylbenzyl)amides d'acide 7-{4-[2-(2,6-dichloro-4-methylphenoxy)-ethoxy] phenyl}-3, 9-diazabicyclo [3.3.1] non-6-ene-6-carboxylique comme inhibiteurs de la renine pour le traitement de l'hypertension. | |
| MA28429B1 (fr) | Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases | |
| BR0210392A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
| JOP20240258A1 (ar) | مشتقات أوكسو إندولينيل أميد لتثبيط nlrp3 واستخداماتها |